Mirum Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 264
- Market Cap
- $2.1B
- Website
- http://www.mirumpharma.com
- Introduction
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
Evaluation of Maralixibat in Pruritus Associated with General Cholestatic Liver Disease (EXPAND)
- Conditions
- Interventions
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06553768
- Locations
- 🇫🇷
Hôpitaux Universitaires de Marseille Timone, Marseille, France
🇮🇹ISMETT - Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo, Italy
🇺🇸Children's Hospital Los Angeles (CHLA), Los Angeles, California, United States
Long-Term Safety and Clinical Outcomes of Livmarli in Patients With Alagille Syndrome (LEAP)
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06193928
- Locations
- 🇺🇸
Section of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics and the Digestive Health Institute, Children's Hospital of Colorado and University of Colorado, Aurora, Colorado, United States
🇺🇸Children's Mercy Kansas City, Department of Gastroenterology, Section of Hepatology, Kansas City, Missouri, United States
🇺🇸Children Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT05050136
- Locations
- 🇯🇵
Toranomon Hospital, Tokyo, Japan
🇺🇸Southern California Research Center, Coronado, California, United States
🇺🇸Science 37, Inc (Remote-homebased Telemedicine), Culver City, California, United States
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
- Conditions
- Interventions
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04729751
- Locations
- 🇵🇱
Instytut Pomnik-Centrum Zdrowia Dziecka, Warsaw, Poland
🇬🇧King's College Hospital, London, United Kingdom
🇺🇸University of California - San Francisco, San Francisco, California, United States
A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT04718961
- Locations
- 🇺🇸
The University of Texas Medical Branch - Galveston, Galveston, Texas, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT04663308
- Locations
- 🇦🇺
University of the Sunshine Coast, Sippy Downs, Australia
🇫🇷Centre Hospitalier Universitaire Grenoble Alpes (CHU Grenoble Alpes), Grenoble, France
🇨🇦McGill University Health Centre - Royal Victoria Hospital, Montréal, Canada
A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)
- Conditions
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Registration Number
- NCT04530994
- Locations
- 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT04524390
- Locations
- 🇻🇳
Vietnam National Children's Hospital, Hanoi, Vietnam
🇨🇳Children's Hospital of Fudan University, Shanghai, China
🇨🇳The Children's Hospital, Zhejiang University School of Medicine, Hanzhou, Zhejiang, China
Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)
- Conditions
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT04270682
- Locations
- 🇧🇷
Travere Investigational Site, São Paulo, SP, Brazil
An Extension Study of Maralixibat in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
- Conditions
- Interventions
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT04185363
- Locations
- 🇸🇬
KK Women's and Children's Hospital, Singapore, Singapore
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Medstar Georgetown University Hospital, Washington, District of Columbia, United States